Linezolid-associated peripheral neuropathy

Jennifer P. Rho, Irene Gaw Sia, Brian A. Crum, Mark B. Dekutoski, Robert T. Trousdale

Research output: Contribution to journalArticle

57 Citations (Scopus)

Abstract

Linezolid is the first drug in a new class of synthetic antimicrobials, the oxazolidinones, to be approved by the Food and Drug Administration. Linezolid is active against methicillin- and vancomycin-resistant gram-positive microorganisms. We describe 2 patients who developed peripheral neuropathy after prolonged treatment with linezolid. Linezolid-associated peripheral neuropathy has not been well documented. Most reported cases of linezolid-associated peripheral neuropathy have occurred in patients who took linezolid for a period longer than the recommended 28 or fewer days. Health care providers must be alert to the potential for serious adverse effects associated with linezolid use, including peripheral neuropathy.

Original languageEnglish (US)
Pages (from-to)927-930
Number of pages4
JournalMayo Clinic Proceedings
Volume79
Issue number7
StatePublished - 2004

Fingerprint

Linezolid
Peripheral Nervous System Diseases
Oxazolidinones
Methicillin Resistance
United States Food and Drug Administration
Vancomycin
Health Personnel

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Rho, J. P., Sia, I. G., Crum, B. A., Dekutoski, M. B., & Trousdale, R. T. (2004). Linezolid-associated peripheral neuropathy. Mayo Clinic Proceedings, 79(7), 927-930.

Linezolid-associated peripheral neuropathy. / Rho, Jennifer P.; Sia, Irene Gaw; Crum, Brian A.; Dekutoski, Mark B.; Trousdale, Robert T.

In: Mayo Clinic Proceedings, Vol. 79, No. 7, 2004, p. 927-930.

Research output: Contribution to journalArticle

Rho, JP, Sia, IG, Crum, BA, Dekutoski, MB & Trousdale, RT 2004, 'Linezolid-associated peripheral neuropathy', Mayo Clinic Proceedings, vol. 79, no. 7, pp. 927-930.
Rho JP, Sia IG, Crum BA, Dekutoski MB, Trousdale RT. Linezolid-associated peripheral neuropathy. Mayo Clinic Proceedings. 2004;79(7):927-930.
Rho, Jennifer P. ; Sia, Irene Gaw ; Crum, Brian A. ; Dekutoski, Mark B. ; Trousdale, Robert T. / Linezolid-associated peripheral neuropathy. In: Mayo Clinic Proceedings. 2004 ; Vol. 79, No. 7. pp. 927-930.
@article{5b91e6be6e33413fa7d8c8cfe5a6643c,
title = "Linezolid-associated peripheral neuropathy",
abstract = "Linezolid is the first drug in a new class of synthetic antimicrobials, the oxazolidinones, to be approved by the Food and Drug Administration. Linezolid is active against methicillin- and vancomycin-resistant gram-positive microorganisms. We describe 2 patients who developed peripheral neuropathy after prolonged treatment with linezolid. Linezolid-associated peripheral neuropathy has not been well documented. Most reported cases of linezolid-associated peripheral neuropathy have occurred in patients who took linezolid for a period longer than the recommended 28 or fewer days. Health care providers must be alert to the potential for serious adverse effects associated with linezolid use, including peripheral neuropathy.",
author = "Rho, {Jennifer P.} and Sia, {Irene Gaw} and Crum, {Brian A.} and Dekutoski, {Mark B.} and Trousdale, {Robert T.}",
year = "2004",
language = "English (US)",
volume = "79",
pages = "927--930",
journal = "Mayo Clinic Proceedings",
issn = "0025-6196",
publisher = "Elsevier Science",
number = "7",

}

TY - JOUR

T1 - Linezolid-associated peripheral neuropathy

AU - Rho, Jennifer P.

AU - Sia, Irene Gaw

AU - Crum, Brian A.

AU - Dekutoski, Mark B.

AU - Trousdale, Robert T.

PY - 2004

Y1 - 2004

N2 - Linezolid is the first drug in a new class of synthetic antimicrobials, the oxazolidinones, to be approved by the Food and Drug Administration. Linezolid is active against methicillin- and vancomycin-resistant gram-positive microorganisms. We describe 2 patients who developed peripheral neuropathy after prolonged treatment with linezolid. Linezolid-associated peripheral neuropathy has not been well documented. Most reported cases of linezolid-associated peripheral neuropathy have occurred in patients who took linezolid for a period longer than the recommended 28 or fewer days. Health care providers must be alert to the potential for serious adverse effects associated with linezolid use, including peripheral neuropathy.

AB - Linezolid is the first drug in a new class of synthetic antimicrobials, the oxazolidinones, to be approved by the Food and Drug Administration. Linezolid is active against methicillin- and vancomycin-resistant gram-positive microorganisms. We describe 2 patients who developed peripheral neuropathy after prolonged treatment with linezolid. Linezolid-associated peripheral neuropathy has not been well documented. Most reported cases of linezolid-associated peripheral neuropathy have occurred in patients who took linezolid for a period longer than the recommended 28 or fewer days. Health care providers must be alert to the potential for serious adverse effects associated with linezolid use, including peripheral neuropathy.

UR - http://www.scopus.com/inward/record.url?scp=3042856503&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3042856503&partnerID=8YFLogxK

M3 - Article

C2 - 15244392

AN - SCOPUS:3042856503

VL - 79

SP - 927

EP - 930

JO - Mayo Clinic Proceedings

JF - Mayo Clinic Proceedings

SN - 0025-6196

IS - 7

ER -